Access Only Access1 Access2 Access3 Drugs News July 5, 2024 Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes
Access Only Access1 Access2 Access3 September 18, 2023 Roche reports positive five-year survival outcomes for extensive-stage small cell lung cancer
